FPTI
FPTI is a SYT-SSX1 fusion protein modulator with selective cytotoxicity in SYT-SSX1-positive synovial sarcoma cells. FPTI down-regulates SYT-SSX1 expression and modulates its downstream target genes. FPTI induces apoptosis in synovial sarcoma cells. FPTI can be used for the research of synovial sarcoma.
For research use only. We do not sell to patients.
- CAS No.: 173374-58-8
- Formula: C15H10FN5
- Molecular Weight:279.27
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Yamato (SYT-SSX1-positive synovial sarcoma), ASKA (SYT-SSX1-positive synovial sarcoma), HEK293 (immortalized embryonic kidney), 143B (sarcoma), A673 (sarcoma)
-
Concentration:10-100 μM (72 h); 40 μM (24, 48, 96 h)
-
Incubation Time:24 h, 48 h, 72 h, 96 h
-
Result:Reduced cell viability by 48.71% in HEK293, 67.35% in ASKA, and 72.48% in Yamato cells at 40 μM for 72 h compared to DMSO controls.
Showed insignificant cytotoxicity at 10 μM and 20 μM.
Induced cytotoxicity in HEK293 cells below 50% viability at 60, 80, 100 μM.
Showed no significant cytotoxicity in 143B or A673 cells.
Achieved IC50 values of 39 μM for ASKA, 33 μM for Yamato, 66 μM for HEK293, 64 μM for 143B, and 70 μM for A673.
-
Cell Line:ASKA (SYT-SSX1-positive synovial sarcoma)
-
Concentration:10 μM, 40 μM (72 h)
-
Incubation Time:72 h
-
Result:Downregulated expression of SYT-SSX1 and its downstream target genes cyclin D1 (CCDN1), β-catenin (CTNNB1), FZD, PDGFRA, COM1, SMARCB1, and P21 at 40 μM.
Induced dose-dependent repression of FZD, CCDN1, SMARCB1, and P21.
Downregulated EGFR and EGR1 only at 10 μM.
Upregulated CDKN2A with treatment.
-
Cell Line:ASKA (SYT-SSX1-positive synovial sarcoma)
-
Concentration:10 μM (IC10), 40 μM (IC50) (24 h)
-
Incubation Time:24 h
-
Result:Altered cell forward and side scatter parameters compared to untreated cells.
Increased cell death to over twice the basal level at 10 μM.
Increased cell death to thrice the basal level at 40 μM.
Induced a marked increase in dual Annexin V/PI staining indicative of late apoptosis at 40 μM.
-
Cell Line:ASKA (SYT-SSX1-positive synovial sarcoma)
-
Concentration:10 μM (non-lethal dose), 40 μM (IC50) (72 h)
-
Incubation Time:72 h
-
Result:Increased the sub-G0 cell population to 31.25% (from 5.385% in untreated cells) and reduced the G0-G1 population to 44.9% (from 69.1% in untreated cells) at 40 μM.
Left the S and G2/M phase populations nearly unchanged at 40 μM.
Increased the sub-G0 population to 15.3% and reduced the G0-G1 population to 53.5% at 10 μM.
- RNA extraction experimental
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- Apoptosis Solutions
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS No. 173374-58-8
-
Molecular Weight 279.27
-
Formula C15H10FN5
-
SMILES
FC1=CC=C2NC=C(C2=C1)C3=NN=NN3C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FPTI Related Classifications
HY-183395 Related Classifications
Powered by Bioz